These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37108685)

  • 1. A Protocol for Simultaneous In Vivo Imaging of Cardiac and Neuroinflammation in Dystrophin-Deficient MDX Mice Using [
    Tang JM; McClennan A; Liu L; Hadway J; Ronald JA; Hicks JW; Hoffman L; Anazodo UC
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy.
    Siemionow M; Langa P; Brodowska S; Kozlowska K; Zalants K; Budzynska K; Heydemann A
    Stem Cell Rev Rep; 2022 Dec; 18(8):2872-2892. PubMed ID: 35590083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exclusive skeletal muscle correction does not modulate dystrophic heart disease in the aged mdx model of Duchenne cardiomyopathy.
    Wasala NB; Bostick B; Yue Y; Duan D
    Hum Mol Genet; 2013 Jul; 22(13):2634-41. PubMed ID: 23459935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Injection of vessel-derived stem cells prevents dilated cardiomyopathy and promotes angiogenesis and endogenous cardiac stem cell proliferation in mdx/utrn-/- but not aged mdx mouse models for duchenne muscular dystrophy.
    Chun JL; O'Brien R; Song MH; Wondrasch BF; Berry SE
    Stem Cells Transl Med; 2013 Jan; 2(1):68-80. PubMed ID: 23283493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human dystrophin expressing chimeric (DEC) cell therapy ameliorates cardiac, respiratory, and skeletal muscle's function in Duchenne muscular dystrophy.
    Siemionow M; Langa P; Harasymczuk M; Cwykiel J; Sielewicz M; Smieszek J; Heydemann A
    Stem Cells Transl Med; 2021 Oct; 10(10):1406-1418. PubMed ID: 34291884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
    Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
    Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of neuromuscular synapse function abnormalities in multiple Duchenne muscular dystrophy mouse models.
    van der Pijl EM; van Putten M; Niks EH; Verschuuren JJ; Aartsma-Rus A; Plomp JJ
    Eur J Neurosci; 2016 Jun; 43(12):1623-35. PubMed ID: 27037492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of skeletal muscle pathology and motor function of dystrophin and utrophin deficient mouse strains.
    van Putten M; Kumar D; Hulsker M; Hoogaars WM; Plomp JJ; van Opstal A; van Iterson M; Admiraal P; van Ommen GJ; 't Hoen PA; Aartsma-Rus A
    Neuromuscul Disord; 2012 May; 22(5):406-17. PubMed ID: 22284942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiomyopathy in the dystrophin/utrophin-deficient mouse model of severe muscular dystrophy is characterized by dysregulation of matrix metalloproteinases.
    Delfín DA; Zang KE; Schill KE; Patel NT; Janssen PM; Raman SV; Rafael-Fortney JA
    Neuromuscul Disord; 2012 Nov; 22(11):1006-14. PubMed ID: 22749475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haploinsufficiency of utrophin gene worsens skeletal muscle inflammation and fibrosis in mdx mice.
    Zhou L; Rafael-Fortney JA; Huang P; Zhao XS; Cheng G; Zhou X; Kaminski HJ; Liu L; Ransohoff RM
    J Neurol Sci; 2008 Jan; 264(1-2):106-11. PubMed ID: 17889902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utrophin haploinsufficiency does not worsen the functional performance, resistance to eccentric contractions and force production of dystrophic mice.
    Boulanger Piette A; Hamoudi D; Marcadet L; Kyomi Labelle F; Ovidiu David R; Bossé S; Argaw A; Frenette J
    PLoS One; 2018; 13(6):e0198408. PubMed ID: 29879154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute AT
    Meyers TA; Heitzman JA; Krebsbach AM; Aufdembrink LM; Hughes R; Bartolomucci A; Townsend D
    J Mol Cell Cardiol; 2019 Mar; 128():51-61. PubMed ID: 30664850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced dimethylarginine degradation improves coronary flow reserve and exercise tolerance in Duchenne muscular dystrophy carrier mice.
    Garbincius JF; Merz LE; Cuttitta AJ; Bayne KV; Schrade S; Armstead EA; Converso-Baran KL; Whitesall SE; D'Alecy LG; Michele DE
    Am J Physiol Heart Circ Physiol; 2020 Sep; 319(3):H582-H603. PubMed ID: 32762558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skeletal muscle fibrosis in the mdx/utrn+/- mouse validates its suitability as a murine model of Duchenne muscular dystrophy.
    Gutpell KM; Hrinivich WT; Hoffman LM
    PLoS One; 2015; 10(1):e0117306. PubMed ID: 25607927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of imaging biomarkers to assess perfusion and glucose metabolism in the skeletal muscle of dystrophic mice.
    Ahmad N; Welch I; Grange R; Hadway J; Dhanvantari S; Hill D; Lee TY; Hoffman LM
    BMC Musculoskelet Disord; 2011 Jun; 12():127. PubMed ID: 21639930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sunitinib inhibits STAT3 phosphorylation in cardiac muscle and prevents cardiomyopathy in the mdx mouse model of Duchenne muscular dystrophy.
    Oliveira-Santos A; Dagda M; Burkin DJ
    Hum Mol Genet; 2022 Jul; 31(14):2358-2369. PubMed ID: 35157045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Xanthine oxidase is hyper-active in Duchenne muscular dystrophy.
    Lindsay A; McCourt PM; Karachunski P; Lowe DA; Ervasti JM
    Free Radic Biol Med; 2018 Dec; 129():364-371. PubMed ID: 30312761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological Inhibition of PKCθ Counteracts Muscle Disease in a Mouse Model of Duchenne Muscular Dystrophy.
    Marrocco V; Fiore P; Benedetti A; Pisu S; Rizzuto E; Musarò A; Madaro L; Lozanoska-Ochser B; Bouché M
    EBioMedicine; 2017 Feb; 16():150-161. PubMed ID: 28089792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Striated muscle activator of Rho signalling (STARS) overexpression in the mdx mouse enhances muscle functional capacity and regulates the actin cytoskeleton and oxidative phosphorylation pathways.
    Sadler KJ; Gatta PAD; Naim T; Wallace MA; Lee A; Zaw T; Lindsay A; Chung RS; Bello L; Pegoraro E; Lamon S; Lynch GS; Russell AP
    Exp Physiol; 2021 Jul; 106(7):1597-1611. PubMed ID: 33963617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of disease specific pathways using in vivo SILAC proteomics in dystrophin deficient mdx mouse.
    Rayavarapu S; Coley W; Cakir E; Jahnke V; Takeda S; Aoki Y; Grodish-Dressman H; Jaiswal JK; Hoffman EP; Brown KJ; Hathout Y; Nagaraju K
    Mol Cell Proteomics; 2013 May; 12(5):1061-73. PubMed ID: 23297347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.